ArticleHaematologica2016
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
Abstract readLetter
In one paragraph
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Optimization of Analytical Performances and Routine Laboratory Implementation of NPM1 Mutation Detection by Digital PCR in the Diagnosis and Monitoring of NPM1 -Mutated Acute Myeloid Leukemias.International journal of laboratory hematology · 2026Article
- NPM1 Measurable Residual Disease: A Narrative Review.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Effect of NPM1 Mutation Subtype and Co-Mutation Patterns on the Outcomes of Acute Myeloid Leukemia.European journal of haematology · 2025Article
- Review
- Influence of Nucleophosmin (Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- The Clinical Impact of NPM1 Mutations and the Effect of Concurrent Mutations in Acute Myeloid Leukemia: Unraveling the Prognostic Significance.Health science reports · 2024Article
- Early Prediction and Streamline of Nucleophosmin Mutation Status in Acute Myeloid Leukemia Using Cup-Like Nuclear Morphology.Medicina (Kaunas, Lithuania) · 2024Article
- Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia.International journal of molecular sciences · 2024Article
- Article
- Could Targeting NPM1c+ Misfolding Be a Promising Strategy for Combating Acute Myeloid Leukemia?International journal of molecular sciences · 2024Review
- Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias.Biomedicines · 2023Review
- Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.Cancer medicine · 2023Article
- An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment.International journal of molecular sciences · 2023Review
- Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (International journal of molecular sciences · 2023Review
- The present and future of measurable residual disease testing in acute myeloid leukemia.Haematologica · 2022Review
- Projection of Expression Profiles to Transcription Factor Activity Space Provides Added Information.Genes · 2022Article
- Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.Leukemia · 2022Article
- Article
- NPM1 gene mutations can be confidently identified in blood DNA months before de novo AML onset.Blood advances · 2022Article
- Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemia.Molecular cytogenetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Tamara AlpermannMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Susanne SchnittgerMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Christiane EderMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Frank DickerMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Manja MeggendorferMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Wolfgang KernMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Christoph SchmidDepartment of Hematology and Oncology, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Carlo AulDepartment of Hematology and Oncology, Helios St. Johannes Klinik, Duisburg, Germany.
Peter StaibDepartment of Hematology and Oncology, St. Antonius Hospital, Eschweiler, Germany.
Clemens-Martin WendtnerDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
Norbert SchmitzDepartment of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany.
Claudia HaferlachMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany.
Torsten HaferlachMLL Munich Leukemia Laboratory, Klinikum Augsburg, University of Munich, Augsburg, Germany torsten.haferlach@mll.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdolescentAdultAgedAged, 80 and overCCAAT-Enhancer-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNA Mutational AnalysisFemalefms-Like Tyrosine Kinase 3Gene ExpressionGene Expression ProfilingHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3IDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseNeoplasm ProteinsNPM1 protein, humanNuclear ProteinsNucleophosminOncogene Proteins, FusionWT1 protein, humanWT1 ProteinsAMLDNMT3A mutationFLT3-ITDmolecular geneticsNPM1 mutationprognosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.